{"id":40458,"date":"2025-09-01T14:05:09","date_gmt":"2025-09-01T06:05:09","guid":{"rendered":"https:\/\/flcube.com\/?p=40458"},"modified":"2025-09-01T14:05:10","modified_gmt":"2025-09-01T06:05:10","slug":"novo-nordisks-steer-study-wegovy-cuts-cardiovascular-risk-57-vs-tirzepatide","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40458","title":{"rendered":"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide"},"content":{"rendered":"\n<p>Danish biopharmaceutical giant Novo Nordisk A\/S (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) presented compelling real\u2011world evidence from the STEER (Semaglutide vs. Tirzepatide in Overweight\/Obesity) study at the European Society of Cardiology (ESC) Congress. The study compared the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity and established cardiovascular disease (CVD) but without diabetes, using Wegovy (semaglutide 2.4\u202fmg) versus tirzepatide.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-findings\">Key Findings<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Wegovy<\/th><th>Tirzepatide<\/th><th>Relative Risk Reduction<\/th><\/tr><\/thead><tbody><tr><td><strong>MACE (no gaps &gt;30\u202fdays)<\/strong><\/td><td>15 events (0.1\u202f%)<\/td><td>39 events (0.4\u202f%)<\/td><td><strong>57\u202f%<\/strong><\/td><\/tr><tr><td><strong>Follow\u2011up<\/strong><\/td><td>3.8\u202fmonths<\/td><td>4.3\u202fmonths<\/td><td>\u2013<\/td><\/tr><tr><td><strong>All\u2011treated patients (any gaps)<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><td><strong>29\u202f%<\/strong><\/td><\/tr><tr><td><strong>Follow\u2011up<\/strong><\/td><td>8.3\u202fmonths<\/td><td>8.6\u202fmonths<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Heart attack, stroke, cardiovascular\u2011related death, or all\u2011cause death<\/strong> were significantly lower in the Wegovy arm when continuous treatment was maintained.<\/li>\n\n\n\n<li>Even when treatment gaps of any length were included, Wegovy still outperformed tirzepatide across all MACE components.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-it-means-for-clinicians\">What It Means for Clinicians<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Continuous therapy is critical<\/strong> \u2013 patients who maintained uninterrupted dosing experienced the greatest benefit.<\/li>\n\n\n\n<li><strong>Weight\u2011loss and cardiovascular protection<\/strong> \u2013 Wegovy\u2019s dual action may offer a therapeutic advantage for patients with CVD and obesity who are not yet diabetic.<\/li>\n\n\n\n<li><strong>Treatment choice<\/strong> \u2013 These real\u2011world data support considering Wegovy over tirzepatide for cardiovascular risk mitigation in this patient cohort.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<p>Novo\u202fNordisk plans to expand STEER\u2019s scope to include longer follow\u2011up and additional cardiovascular endpoints. The company will also explore the impact of treatment adherence on outcomes in larger, prospective registries.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Danish biopharmaceutical giant Novo Nordisk A\/S (NYSE: NVO) presented compelling real\u2011world evidence from the STEER&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40459,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,148,860],"class_list":["post-40458","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"At the ESC Congress 2025, Novo\u202fNordisk revealed real\u2011world data showing Wegovy (semaglutide 2.4\u202fmg) reduces major adverse cardiovascular events by 57\u202f% compared with tirzepatide in overweight\/obese patients with established CVD and no diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40458\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide\" \/>\n<meta property=\"og:description\" content=\"At the ESC Congress 2025, Novo\u202fNordisk revealed real\u2011world data showing Wegovy (semaglutide 2.4\u202fmg) reduces major adverse cardiovascular events by 57\u202f% compared with tirzepatide in overweight\/obese patients with established CVD and no diabetes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40458\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T06:05:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-01T06:05:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40458#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40458\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide\",\"datePublished\":\"2025-09-01T06:05:09+00:00\",\"dateModified\":\"2025-09-01T06:05:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40458\"},\"wordCount\":242,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40458#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0102.webp\",\"keywords\":[\"Clinical trial results\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40458#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40458\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40458\",\"name\":\"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40458#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40458#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0102.webp\",\"datePublished\":\"2025-09-01T06:05:09+00:00\",\"dateModified\":\"2025-09-01T06:05:10+00:00\",\"description\":\"At the ESC Congress 2025, Novo\u202fNordisk revealed real\u2011world data showing Wegovy (semaglutide 2.4\u202fmg) reduces major adverse cardiovascular events by 57\u202f% compared with tirzepatide in overweight\\\/obese patients with established CVD and no diabetes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40458#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40458\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40458#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40458#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide - Insight, China&#039;s Pharmaceutical Industry","description":"At the ESC Congress 2025, Novo\u202fNordisk revealed real\u2011world data showing Wegovy (semaglutide 2.4\u202fmg) reduces major adverse cardiovascular events by 57\u202f% compared with tirzepatide in overweight\/obese patients with established CVD and no diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40458","og_locale":"en_US","og_type":"article","og_title":"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide","og_description":"At the ESC Congress 2025, Novo\u202fNordisk revealed real\u2011world data showing Wegovy (semaglutide 2.4\u202fmg) reduces major adverse cardiovascular events by 57\u202f% compared with tirzepatide in overweight\/obese patients with established CVD and no diabetes.","og_url":"https:\/\/flcube.com\/?p=40458","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-01T06:05:09+00:00","article_modified_time":"2025-09-01T06:05:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40458#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40458"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide","datePublished":"2025-09-01T06:05:09+00:00","dateModified":"2025-09-01T06:05:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40458"},"wordCount":242,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40458#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0102.webp","keywords":["Clinical trial results","Novo Nordisk","NYSE: NVO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40458#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40458","url":"https:\/\/flcube.com\/?p=40458","name":"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40458#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40458#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0102.webp","datePublished":"2025-09-01T06:05:09+00:00","dateModified":"2025-09-01T06:05:10+00:00","description":"At the ESC Congress 2025, Novo\u202fNordisk revealed real\u2011world data showing Wegovy (semaglutide 2.4\u202fmg) reduces major adverse cardiovascular events by 57\u202f% compared with tirzepatide in overweight\/obese patients with established CVD and no diabetes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40458#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40458"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40458#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0102.webp","width":1080,"height":608,"caption":"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40458#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo\u202fNordisk\u2019s STEER Study: Wegovy Cuts Cardiovascular Risk 57\u202f% vs. Tirzepatide"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40458"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40458\/revisions"}],"predecessor-version":[{"id":40460,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40458\/revisions\/40460"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40459"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}